Abstract
The active metabolite (JM118) of the oral platinum analog satraplatin (JM216) was investigated for potential synergism with erlotinib, an epidermal growth factor receptor (EGFR) inhibitor. JM118 sensitivity of 7 cancer cell lines (ovarian: 2008, A2780; colon: Lovo92, WiDr; lung: A549, SW1573; epidermoid: A431), was enhanced most pronounced when JM118 preceded erlotinib, which was associated with increased formation of DNA-platinum adducts. The combination increased G2/M phase accumulation and enhanced apoptosis. JM118 increased the phosphorylation of the cell cycle proteins CDK2 and CHK1 after 24 hr exposure. JM118/erlotinib enhanced Erk and Akt phosphorylation after 2 hr. JM118 significantly decreased the phosphorylation of PTEN, VEGFR, EPHA1, ERBB4, FGF-R, andSTAT3 by 20 (PTEN) to >90% (STAT3). Conclusion: Erlotinib enhanced the effects of JM118, even in cells with mutations in Ras. The mechanism of synergy involved a combination of effects on platinum-DNA adduct formation, cell cycle distribution and signaling.
Keywords: Akt, colon cancer, Erk, erlotinib, lung cancer, satraplatin, signaling.
Current Drug Targets
Title:Modulation of Signaling Enhances the Efficacy of the Combination of Satraplatin and Erlotinib
Volume: 15 Issue: 14
Author(s): Abolfazl Avan, Auke D. Adema, Eveline K. Hoebe, Charlotte M. Huijts, Amir Avan, Gareth J. Veal, Rob Ruijtenbeek, Katja Wosikowski and Godefridus J. Peters
Affiliation:
Keywords: Akt, colon cancer, Erk, erlotinib, lung cancer, satraplatin, signaling.
Abstract: The active metabolite (JM118) of the oral platinum analog satraplatin (JM216) was investigated for potential synergism with erlotinib, an epidermal growth factor receptor (EGFR) inhibitor. JM118 sensitivity of 7 cancer cell lines (ovarian: 2008, A2780; colon: Lovo92, WiDr; lung: A549, SW1573; epidermoid: A431), was enhanced most pronounced when JM118 preceded erlotinib, which was associated with increased formation of DNA-platinum adducts. The combination increased G2/M phase accumulation and enhanced apoptosis. JM118 increased the phosphorylation of the cell cycle proteins CDK2 and CHK1 after 24 hr exposure. JM118/erlotinib enhanced Erk and Akt phosphorylation after 2 hr. JM118 significantly decreased the phosphorylation of PTEN, VEGFR, EPHA1, ERBB4, FGF-R, andSTAT3 by 20 (PTEN) to >90% (STAT3). Conclusion: Erlotinib enhanced the effects of JM118, even in cells with mutations in Ras. The mechanism of synergy involved a combination of effects on platinum-DNA adduct formation, cell cycle distribution and signaling.
Export Options
About this article
Cite this article as:
Avan Abolfazl, Adema D. Auke, Hoebe K. Eveline, Huijts M. Charlotte, Avan Amir, Veal J. Gareth, Ruijtenbeek Rob, Wosikowski Katja and Peters J. Godefridus, Modulation of Signaling Enhances the Efficacy of the Combination of Satraplatin and Erlotinib, Current Drug Targets 2014; 15 (14) . https://dx.doi.org/10.2174/1389450115666141107110321
DOI https://dx.doi.org/10.2174/1389450115666141107110321 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Physiology of Folic Acid in Health and Disease
Current Drug Metabolism Inhibitory Effects of Novel SphK2 Inhibitors on Migration of Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Pulmonary Squamous Papilloma Complicating Recurrent Tracheal Papillomatosis
Current Respiratory Medicine Reviews A Potential Anticancer Agent 1,2-di(quinazolin-4-yl)diselane
Letters in Drug Design & Discovery Drug Delivery Systems with Modified Release for Systemic and Biophase Bioavailability
Current Clinical Pharmacology The Screening of Renoprotective Agents by 99mTc-DMSA: A Review of Preclinical Studies
Current Radiopharmaceuticals The Effect of Lipoic Acid on Macro and Trace Metal Levels in Living Tissues Exposed to Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Quantum Dots in the Therapy: Current Trends and Perspectives
Mini-Reviews in Medicinal Chemistry Immunoproteasome-Selective Inhibitors: A Promising Strategy to Treat Hematologic Malignancies, Autoimmune and Inflammatory Diseases
Current Medicinal Chemistry Cyclooxygenases in Cancer: Chemoprevention and Sensitization to Conventional Therapies
Mini-Reviews in Medicinal Chemistry Neoisoliquiritigenin Inhibits Tumor Progression by Targeting GRP78-β- catenin Signaling in Breast Cancer
Current Cancer Drug Targets Regulation of EMT by Notch Signaling Pathway in Tumor Progression
Current Cancer Drug Targets From Bacteria to Antineoplastic: Epothilones A Successful History
Anti-Cancer Agents in Medicinal Chemistry Silencing of Disease-related Genes by Small Interfering RNAs
Current Molecular Medicine Hepatocyte FRS2α is Essential for the Endocrine Fibroblast Growth Factor to Limit the Amplitude of Bile Acid Production Induced by Prandial Activity
Current Molecular Medicine iNOS: A Potential Therapeutic Target for Malignant Glioma
Current Molecular Medicine Hypoxia Responsive Drug Delivery Systems in Tumor Therapy
Current Pharmaceutical Design Cytotoxicity, Anti-diabetic, and Hepato-protective Potential of <i>Ajuga bracteosa</i>-conjugated Silver Nanoparticles in Balb/c Mice
Current Pharmaceutical Biotechnology A Review on Natural Sources Derived Protein Nanoparticles as Anticancer Agents
Current Topics in Medicinal Chemistry Targeting Epidermal Growth Factor Receptor in Solid Tumors: Critical Evaluation of the Biological Importance of Therapeutic Monoclonal Antibodies
Current Medicinal Chemistry